Insight Molecular Diagnostics
IMDX
30 hedge funds and large institutions have $49.2M invested in Insight Molecular Diagnostics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.
19,696% more capital inflows, than outflows
Capital inflows: $20.9M | Capital outflows: $105K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
11% more funds holding
Funds holding: 27 → 30 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.68% less ownership
Funds ownership: 62.94% → 56.27% (-6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadwood Capital
New York
|
+$14M |
| 2 |
AIC
AWM Investment Company
New York
|
+$5.53M |
| 3 |
Pura Vida Investments
New York
|
+$791K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$132K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
-$31.5K |
| 2 |
FNY Investment Advisers
New York
|
-$27.6K |
| 3 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$26K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$8.51K |
| 5 |
Defender Capital
Charlotte,
North Carolina
|
-$7.3K |
IMDX Hedge Fund Activity: Q1 2025 in Review
30 of the 7,481 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2025, worth a combined $49.2M — up 146% from $20M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IMDX positions and 5 closed out — a net gain of 3 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $14M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $31.5K sold.
- 30 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2025, up from 27 in Q4 2024.
- Funds reported $49.2M of Insight Molecular Diagnostics stock for Q1 2025, up 146% quarter-over-quarter.
- 8 funds opened new Insight Molecular Diagnostics positions in Q1 2025 and 5 closed out, a net change of +3 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2025 was Broadwood Capital, an estimated $14M added.
- The largest Insight Molecular Diagnostics seller in Q1 2025 was Two Sigma Securities, an estimated $31.5K sold.
Based on aggregated 13F filings for Q1 2025.